Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors

被引：0

作者：

Hong Chen

Yan Wen

Yun Zeng

Lie Lin

Bihong Sun

Hongqian Zhu

Huiqing He

Xiaotao Wang

Waiyi Zou

Caifeng Zheng

Liling Zheng

Jinxiong Huang

Liping Pang

Jixian Huang

Yuming Zhang

Haiqing Lin

Zelin Liu

Wanshou Zhu

Qiang Wang

Xuan Zhou

Xiaoli Liu

Hong Qu

Zhenfang Liu

Xin Du

Na Xu

机构：

[1] Nanfang Hospital,Department of Hematology

[2] Southern Medical University,Department of Hematology

[3] Yunnan Hematology Hospital,Department of Hematology

[4] First People’ Hospital of Yunnan,Department of Hematology

[5] Affiliated Hospital of Kunming University of Science and Technology,Department of Hematology

[6] First Affiliated Hospital of Kunming Medical University,Department of Hematology

[7] Hematology Research Center of Yunnan Province,Department of Hematology

[8] Hainan General Hospital,Department of Hematology

[9] People’s Hospital of Guangxi Zhuang Autonomous Region,Department of Hematology

[10] Guizhou Provincial People’s Hospital,Department of Hematology

[11] Zhongshan People’s Hospital,Department of Hematology

[12] Guilin Medical University Affiliated Hospital,Department of Hematology

[13] The First Affiliated Hospital,Department of Hematology

[14] Sun Yat-Sen University,Department of Hematology

[15] Shenzhen Bao An People’s Hospital,Department of Hematology

[16] The Second People’s Hospital of Guangdong Province,Department of Hematology

[17] Liuzhou People’s Hospital,Department of Hematology

[18] Peking University Shenzhen Hospital,Department of Hematology

[19] Yue Bei People’s Hospital,Department of Hematology

[20] Shantou University Medical College,Department of Hematology

[21] Affiliated Hospital of Guangdong Medical University,Department of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform

[22] Shenzhen People’s Hospital,undefined

[23] Second Clinical Medical College of Jinan University,undefined

[24] First Affiliated Hospital of Southern University of Science and Technology,undefined

[25] Huazhong University of Science and Technology Union Shenzhen Hospital,undefined

[26] Gaozhou People’s Hospital,undefined

[27] Panyu Central Hospital,undefined

[28] The First Affiliated Hospital of Guangxi Medical University,undefined

[29] The First Affiliated Hospital of Shenzhen University,undefined

[30] Shenzhen Second People’s Hospital,undefined

[31] Shenzhen University School of Medicine,undefined

来源：

Oncology and Therapy | 2024年 / 12卷

关键词：

Chronic myeloid leukemia; Patient; Physician; Quality of life; Discrepancies;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：131 / 145

页数：14

共 50 条

[41] Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors
Tomonori Nakazato
Noriyoshi Iriyama
Michihide Tokuhira
Maho Ishikawa
Eriko Sato
Tomoiku Takaku
Kei-Ji Sugimoto
Hiroyuki Fujita
Isao Fujioka
Yuta Kimura
Yoshinobu Aisa
Eisaku Iwanaga
Norio Asou
Masahiro Kizaki
Yoshihiro Hatta
Norio Komatsu
Tatsuya Kawaguchi
Medical Oncology, 2018, 35
[42] Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors
Nakazato, Tomonori
Iriyama, Noriyoshi
Tokuhira, Michihide
Ishikawa, Maho
Sato, Eriko
Takaku, Tomoiku
Sugimoto, Kei-Ji
Fujita, Hiroyuki
Fujioka, Isao
Kimura, Yuta
Aisa, Yoshinobu
Iwanaga, Eisaku
Asou, Norio
Kizaki, Masahiro
Hatta, Yoshihiro
Komatsu, Norio
Kawaguchi, Tatsuya
MEDICAL ONCOLOGY, 2018, 35 (07)
[43] Breastfeeding in a patient with chronic myeloid leukemia during tyrosine kinase inhibitor therapy
Terao, Ryuta
Nii, Mitsumaro
Asai, Hiroko
Nohara, Fumikatsu
Okamoto, Toshio
Nagaya, Ken
Azuma, Hiroshi
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (03) : 756 - 760
[44] Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views
Tromp, Vashti N. M. F.
Timmers, Lonneke
Koningen, Leanne
Janssen, Jeroen J. W. M.
Westerweel, Peter E.
Geelen, Inge G. P.
de Jong, Jan
Beckeringh, Jan J.
Boons, Christel C. L. M.
Hugtenburg, Jacqueline G.
LEUKEMIA & LYMPHOMA, 2021, 62 (03) : 649 - 658
[45] Mutations of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
Kihel, I.
Nachi, M.
Bekadja, M. A.
CLINICA CHIMICA ACTA, 2022, 530 : S334 - S335
[46] Unplanned discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia
Tsutsumi, Yutaka
Ito, Shinichi
Ohigashi, Hiroyuki
Shiratori, Souichi
Teshima, Takanori
MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (01) : 89 - 92
[47] Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system
Malkan, U. Y.
Haznedaroglu, I. C.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (12) : 5493 - 5506
[48] Treating Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors
Gale, Robert Peter
Goldman, John M.
ACTA HAEMATOLOGICA, 2013, 130 (03) : 192 - 195
[49] Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia
Shima, Haruko
Kada, Akiko
Tanizawa, Akihiko
Sato, Iori
Tono, Chikako
Ito, Masaki
Yuza, Yuki
Watanabe, Akihiro
Kamibeppu, Kiyoko
Uryu, Hideko
Koh, Katsuyoshi
Imai, Chihaya
Yoshida, Nao
Koga, Yuhki
Fujita, Naoto
Saito, Akiko M.
Adachi, Souichi
Ishii, Eiichi
Shimada, Hiroyuki
PEDIATRIC BLOOD & CANCER, 2022, 69 (08)
[50] The Association of Tyrosine Kinase Inhibitors with Obesity in Chronic Myeloid Leukemia
Rajan, Raeesha
Karia, Esha
Samaan, M. Constantine
Balakumaran, Janatani
Golemiec, Breanne
Spatafora, Laura
Banfield, Laura
Athale, Uma
Thabane, Lehana
Fleming, Adam
Samaan, Constantine
OBESITY, 2021, 29 : 172 - 172

← 1 2 3 4 5 →